Literature DB >> 8889347

A note on quantifying follow-up in studies of failure time.

M Schemper1, T L Smith.   

Abstract

Mesh：

Year:  1996        PMID： 8889347     DOI： 10.1016/0197-2456(96)00075-x

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN： 0197-2456


× No keyword cloud information.
  694 in total

1.  Numbers needed to treat derived from meta-analysis. Are an absurdity.

Authors:  B G Charlton
Journal:  BMJ       Date:  1999-10-30

2.  Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Authors:  Song Gao; Seth Stein; Elena N Petre; Waleed Shady; Jeremy C Durack; Carole Ridge; Prasad Adusumilli; Natasha Rekhtman; Stephen B Solomon; Etay Ziv
Journal:  Cardiovasc Intervent Radiol       Date:  2017-08-02       Impact factor: 2.740

3.  A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer.

Authors:  Natsuko T Okita; Taito Esaki; Eishi Baba; Daisuke Sakai; Shinya Tokunaga; Hiroya Takiuchi; Nobuyuki Mizunuma; Kengo Nagashima; Ken Kato
Journal:  Invest New Drugs       Date:  2011-12-10       Impact factor: 3.850

4.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

5.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

6.  Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study.

Authors:  Itsuro Jinnai; Tohru Sakura; Motohiro Tsuzuki; Yasuhiro Maeda; Noriko Usui; Masayuki Kato; Hirokazu Okumura; Taiichi Kyo; Yasunori Ueda; Yuji Kishimoto; Fumiharu Yagasaki; Kosuke Tsuboi; Shigeo Horiike; Jin Takeuchi; Masako Iwanaga; Yasushi Miyazaki; Shuichi Miyawaki; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Int J Hematol       Date:  2010-09-10       Impact factor: 2.490

7.  Simultaneous marginal survival estimators when doubly censored data is present.

Authors:  Olga Julià; Guadalupe Gómez
Journal:  Lifetime Data Anal       Date:  2010-10-01       Impact factor: 1.588

8.  Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.

Authors:  Janick Weberpals; Lina Jansen; Myrthe P P van Herk-Sukel; Josephina G Kuiper; Mieke J Aarts; Pauline A J Vissers; Hermann Brenner
Journal:  Eur J Epidemiol       Date:  2017-09-01       Impact factor: 8.082

Review 9.  Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.

Authors:  Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith
Journal:  Leuk Res       Date:  2017-08-30       Impact factor: 3.156

10.  Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.

Authors:  Shadi Lalezari; Arthur P Chou; Anh Tran; Orestes E Solis; Negar Khanlou; Weidong Chen; Sichen Li; Jose A Carrillo; Reshmi Chowdhury; Julia Selfridge; Desiree E Sanchez; Ryan W Wilson; Mira Zurayk; Jonathan Lalezari; Jerry J Lou; Laurel Ormiston; Karen Ancheta; Robert Hanna; Paul Miller; David Piccioni; Benjamin M Ellingson; Colin Buchanan; Paul S Mischel; Phioanh L Nghiemphu; Richard Green; He-Jing Wang; Whitney B Pope; Linda M Liau; Robert M Elashoff; Timothy F Cloughesy; William H Yong; Albert Lai
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.